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Old Disease, New Targets
Part-I, Solid malignancies
Shiyam Kumar, Nehal Masood, Asim Jamal Shaikh
Section of Hematology/Oncology, Department of Medicine, The Aga Khan University Hospital, Karachi.
Abstract
Targeted agents are now an integral part of treatment
regimens for some cancers. Trastuzumab is established in
treatment of human epidermal receptor 2 (Her2) positive
breast cancers, with improvements in both, the disease free
and over all survival. Monoclonal antibody (MoAB) against
vascular growth factor receptor (VEGF), bevacizumab and
cetuximab a MoAB against epidermal growth factor receptor
(EGFR) are establishing their role in a many cancers after
making their mark in colorectal cancer. Sorafenib and
sunitinib have success stories in renal carcinoma. The
Sorafenib Hepatocellular Carcinoma Assessment Randomized
Protocol (SHARP) trial has established sorafenib role in
advanced hepatocellular carcinoma, while in gastrointestinal
tumors; imatinib and sunitinib have proven role. At this point
in time side effect profile of all these agents appears relatively
safe however cost for developing countries remains an issue.
Introduction
After impressive results of rituximab in the treatment
of Non-Hodgkins lymphoma, role of Targeted agents in the
solid tumors continues to evolve and so does the list of agents
available. The current list of available agents includes
trastuzumab, bevacizumab, cetuximab, panitumumab,
lapatinib, gefitinib, erlotinib, imatinib, sunitinib, and sorafenib
(Table). The efficacy of many agents continues to result in
improved survival and of many more continues to be
investigated.
Trastuzumab:
Approximately 20-30% of invasive breast cancers
over-express Her2. Her2 also called erb B-2 receptors belong
to a family of EGFR. Generally considered to be a negative
prognostic indicator for breast cancer; studies are now focused
on assessment of its association with efficacy of other
chemotherapeutic agents including alkylating agents.
Trastuzumab a MoAB against Her2/neu exerts its action
through activating the immune system, increasing the
endolysis of Her2, stops receptor dimerization and shedding
of extracellular domain. Associated toxicities are infusion
related hypersensitivity and cardiomyopathy.1
Trastuzumab for Breast Cancer in adjuvant
setting:
HERA (Herceptin Adjuvant), an international trial,
accrued >5000 women with Her2 amplified, early stage breast
cancer. Patients were randomized to observation (n=1693),
trastuzumab for 1 year (n=1694) or 2 years (n=1694) after
receiving at least 4 cycles of chemotherapy. More events were
observed in observation arm than in treatment arm (220 vs.127,
unadjusted hazard ratio (HR), 0.54; p<0.0001) with a benefit of
8.4% at 2 years for disease free survival (DFS) (Figure 1). No
survival advantage was observed.2With a median follow-up of
23.5 months of HERA, more events of recurrence were
observed in observation arm (321 vs. 218, p<0.0001).  More
patients have died in observation arm (90 vs. 53, unadjusted
HR, 0.66; p=0.01). Absolute benefit for DFS and over all
survival (OS) was 6.3% and 2.7% respectively at 3 years. More
women on trastuzumab developed severe congestive cardiac
failure (CCF) (p<0.0001) and grade 3/4 adverse events (AEs,
p<0.0001).3 No added advantage of continuing therapy for
more than one year was observed.
National Surgical Adjuvant Breast and Bowel Project
trial B-31( NSABP-B 31) and the North Central Cancer
Treatment Group trial N9831 (NCCTG N9831)  were the two
other trials which demonstrated results in favour of herceptin.
The B-31 study compared standard doxorubicin and
cyclophosphamide (AC) followed by paclitaxil with same
chemotherapy with trastuzumab for 1 year and N9831
compared four cycles of AC followed by weekly paclitaxel for
12 weeks (group 1), 4 cycles of AC and paclitaxel followed by
1 year of trastuzumab (group 2) and 4 cycles of AC followed
by paclitaxel and trastuzumab starting together for 1 year
(group 3). Combined results of both trials were released. In B-
31, 1736 patients and 1615 patients in N9831 were assessable.
With median follow-up of 2 years more events were recorded
in control group (261 vs. 133, p<0.0001). Absolute differences
of 11.8% at 3 years and 18.2% at 4 years for DFS and 2.5% at
3 years and 4.8% at 4 years for OS were observed.4
In Finland Herceptin (FinHer) study, herceptin was
used for a shorter period of time with relatively same benefit
obtained, although the number of patients accrued was less
than the famous HERA trial. Women with Her2 amplified
breast cancer were randomized to docetaxel for 3 cycles
followed by 3 cycles of 5-Flourouracil, epirubicin and
cyclophosphamide (FEC) with (n = 54) or without
trastuzumab (n = 58) or 3 cycles of vinorelbine followed by 3
cycles of FEC with (n = 62) or without trastuzumab (n = 58).
Trastuzumab was administered on day 1 of docetaxel or
vinorelbine in weekly doses for 9 weeks. Recurrences were
less common in trastuzumab group (12 vs. 27, p = 0.01). OS
was also better for trastuzumab arm (6 vs. 14 deaths, p = 0.07).
Asymptomatic 15% decline in ejection fraction was recorded
in 3.5% patients on trastuzumab.5
In the Breast Cancer International Research Group
006 trial (BCIRG 006), women with Her2 positive breast
cancer were randomly assigned to receive AC followed by
docetaxel alone (n=1073), AC followed by docetaxel and
trastuzumab for 1 year (n=1074) and docetaxel,
carboplatien and trastuzumab for 1 year (n=1075). Second
interim analysis revealed better DFS and OS for
trastuzumab containing arms with decreased risk of death
as well.1,6
Trastuzumab for Metastatic Breast Cancer:
In a phase III trial published in 2001 which
involved 469 breast cancer patients with metastasis
received chemotherapy either AC or paclitaxil both with or
without trastuzumab. At the median follow up of 30
months, odds were in favour of trastuzumab in addition to
chemotherapy, in terms of time to progression (TTP, 7.4
vs. 4.6 months)  and over all response rate (ORR, 50 % vs.
32 % p= <0.001).7
Robert et al8 reported a trial of trastuzumab combined
or not to paclitaxil and carboplatin in Her2/neu over
expressive metastatic breast cancer patients. ORR was in
favour of herecptin (52% vs. 36 %; p = 0.04), improvement in
median progression free survival (PFS, 10.7 vs. 7.1 months)
and also in OS (38 vs. 31 months) were reported.
Bevacizumab:
Vascular granter factor receptor (VEGF) is a
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Table.
Drug Name FDA Approval Approved Indications Side Effect Profile
Trastuzumab November 2006
Bevacizumab 2004
2006
2008
Cetuximab 2004
2006
Panitumumab 2006
Lapatinib 2007
Gefitinib 2005
Erlotinib 2004
2005
Sunitinib 2006
Sorafenib 2005
2007
CRC = Colorectal Cancer, EGFR = Epideraml Growth Factor Receptor, GIST = Gastrointestinal Stromal Tumor, 
HCC = Hepatocellular Cancer, NSCLC = Non-Small Cell Lung Cancer, PPE = Palmar-plantar erythrodysesthesia, 
RCC = Renal Cell Carcinoma  (URL  http://www.cancer.gov/cancertopics)
Her2 positive Breast Cancer
First and second-line treatment of Metastatic
CRC 
First-Line Treatment of NSCLC 
Metastatic HER2-Negative Breast Cancer
CRC
Head and Neck cancer
EGFR expressing CRC
(as second line)
Her2 over expressing advancer or metastatic
Breast Cancer in combination with Capecitabine
Metastatic NSCLC
Advanced or Metastatic NSCLC
Advanced, unresectable or Metastatic Pancreatic
Cancer in combination with Gemcitabine
GIST (progressing on or intolerant to Imatinib)
RCC (advanced or metastatic)
RCC (advanced or metastatic)
HCC
Cardiomyopathy,  Pulmonary toxicity (respiratory
failure, pneumonitis, pulmonary infiltrates),
Infusion reactions, Febrile neutropenia
Hypertension, Proteinuria, Haemorrhage, Febrile
neutropenia, Arterial thrombo- embolic events,
Reversible posterior leukoencephalopathy
syndrome
Acneform rash, Asthenia/malaise, Fever, Nausea,
Constipation and Diarrhoea.
Pulmonary fibrosis, Severe dermatologic toxicity
complicated by infectious sequelae and septic
death, Infusion reactions, Abdominal pain,
Hypomagnesemia, Nausea.
Diarrhea, PPE, Nausea, Rash, Vomiting, and
Fatigue.
Fatigue, Rash, Nausea, Anorexia, and Diarrhoea
Hypertension, Diarrhea, Hand-foot syndrome,
Nausea, Vomiting, Mucositis, Bleeding and
Myelosuppression.
Reversible skin rashes, Hand-foot syndrome,
Diarrhoea, Hypertension, Sensory neuropathic
changes, Alopecia, Mucositis, and Haemorrhage.
diffusible glycoprotein produced both by normal and
neoplastic cells. It is one of the important regulators for
physiologic and pathological angiogenesis. Preclinical
studies have demonstrated the efficacy of murine
antihuman MoAB against VEGF in suppression of human
tumour xenografts. Humanized variant of that murine
antibody bevacizumab has been evaluated for various
malignancies. Bevacizumab is believed to have a strong
angiogenic role. An  added advantage of bevacizumab is to
decrease elevated interstitial pressure and alter tumour
vasculature, by virtue of which it  increases the
chemotherapy delivery towards tumours.9
Bevacizumab for Renal Cell Cancer (RCC):
In a double-blind, phase III trial, patients with
metastatic RCC were randomized to bevacizumab and
interferon alfa (IFN, n = 327) or IFN and placebo (n = 322).
The primary endpoint of OS has not matured till the release of
the results while the PFS (10.2 vs. 5.4 months p = 0·0001),
time to treatment failure (TTF, 7·7 vs. 4·4 months, p = 0·0003)
and ORR (70% vs. 39%, p = 0·0001) were better for
bevacizumab group. Significant AEs in bevacizumab arm
were grade 3/4 gastrointestinal perforations, thromboembolic
events, hypertension and proteinuria requiring treatment
discontinuation.10
Bevacizumab for Metastatic Colorectal Cancer
(mCRC):
Bevacizumab was granted FDA approval in mCRC
on the basis of a phase III trial in which patients with
mCRC were treated with irinotecan, 5- Flourouracil (5FU)
and leucovorin with or without bevacizumab, with about 50
% having had already received a previous therapy. Addition
of Becacizumab (AvastinTM) fared better than those
without. OS was in favour of bevacizumab arm (20.3 vs.
15.6 months, p<0.001) and reduced the risk of death to
34%. One year OS (74.3% vs. 63.4%, p<0.001), median
PFS (10.6 vs. 6.2 months, p<0.001), response rate (44.8%
vs. 34.8%, p = 0.004); and the median duration of response
(10.4 vs. 7.1 months, p = 0.001) was also better with
bevacizumab.9
In Eastern Co-operative Oncology Group (ECOG)
study, E3200, patients with mCRC received 5FU, leucovorin
and oxaliplatin (FOLFOX) with or without bevacizumab.
Confirmed responses were better for combination therapy
(22.7% vs. 8.6%, p = 0.0001). Grades 3/4 hypertension,
proteinuria, bleeding, vomiting and neuropathy were more
common in combination therapy arm.11
Bevacizumab for Metastatic Breast cancer
(MBC):
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Figure 1: Kaplan-Meier Curves Showing Disease-free Survival (Panel A), 
Time to Distant Recurrence (Panel B),
and Overall Survival (Panel C).
The hazard ratios (with 95 percent confidence intervals and P values) are for the
patients assigned to receive trastuzumab for one year, as compared with those
assigned to observation, and were obtained from the unadjusted Cox (With
permission from Ref: No. 2)
Women with MBC were randomized to bevacizumab
and capecitabine (n = 232) or capecitabine alone (n = 230) in
a phase III trial. ORR were better for patients treated with
combination therapy (19.8% vs. 9.1%, p = 0.001), however
this did not translate into better PFS or OS.12
A phase III study, randomized patients with MBC to
receive paclitaxel at 90 mg/m2 on day 1, 8 and 15 q 28 days
with bevacizumab at 10 mg/kg on day 1 and 15 (n = 347) or
paclitaxel alone (n = 326). Combination treatment
substantially improved PFS (median, 11.8 vs. 5.9 months,
p<0.001) and ORR (36.9% vs. 21.2%, P<0.001), with no
significant improvement in OS (Figure 2). Hypertension,
proteinuria, headache, cereberovascular ischaemia were more
commonly seen in bevacizumab arm.13
Bevacizumab for Non-Small Cell Lung Cancer
(NSCLC):
Patients with stage IIIB/IV, NSCLC were enrolled on
a phase III trial to receive paclitaxel and carboplatin alone (n
= 433) or with bevacizumab (n = 417). With a median follow-
up of 19 months, median OS is longer for bevacizumab arm
(12.3 vs. 10.3 months, p = 0.003), with better 1 and 2 year
survival rates 51% vs. 44% and 23% vs. 15% respectively.
Substantially improved median PFS (6.2 months vs. 4.5
months, p<0.001) and response rate ( 35% vs. 15%, p<0.001)
were observed for bevacizuamb arm.14
Bevacizumab for Glioblastoma Multiforme
(GBM):
Patients with relapsed GBM received bevacizuamb
and irinotecan in a phase II study. Of 35 registered patients 23
initial patients received therapy in a 2 weekly fashion and later
12 patients received 6 weekly regimen. Bevacizumab was
administered at 10mg/kg q 14 days for cohort 1 and at 15
mg/kg q 21 days for cohort 2. PR observed by 20 patients and
positron emission tomograpghy (PET) scan showed no
residual high grade tumour in 6 patients after 1 year of
treatment. The 6-months PFS and OS were 46% and 77%
respectively.15
Cetuximab:
EGFR is amplified on many cancers including lung,
breast, kidney, colon, prostate, brain, ovarian, pancreatic and
head and neck cancers and portrays poor outcome. EGFR is an
important mediator for cell proliferation, differentiation,
migration, angiogenesis and apoptosis.16,17
Cetuximab is a chimeric MoAB with high affinity and
specificity for EGFR. It not only halts the receptor mediated
effects but also has synergistic effect for chemo and
radiotherapy.16,17
Cetuximab for Metastatic Colorectal Cancer
(mCRC):
A European study randomized patients with mCRC to
receive cetuximab alone (n = 111) or with irinotecan (n = 228).
Cetuximab was administered as loading dose of 400 mg/m2
followed by 250 mg/m2 weekly infusion. Intention to treat
(ITT) analysis revealed better ORR for combination therapy
(22.9% vs. 10.8%, p = 0.007). Better disease control was
observed with combination therapy (55.5% vs. 32.4%,
p<0.001). Combination therapy reduced the risk of
progression by 46% (p<0.001), improved median TTP (4.1 vs.
1.5 months) and median OS (8.6 vs. 6.9 months). Grade 3/4
AEs were more common in combination arm (p<0.001).17
Another randomized study assigned patients with
mCRC to receive best supportive care (BSC, n = 285) or
cetuximab and BSC alone (n = 287). Patients in treatment arm
lived longer (6.1 vs. 4.6 months, HR 0.77, p = 0.005).
Cetuximab therapy improved PR (8% vs. 0%, p<0.001) and
SD (31.4% vs. 10.9%, p<0.001). AEs were significantly high
for treatment group (p<0.001).18
Cetuximab for Head and Neck Cancer (HNC):
An international, phase III study enrolled patients with
locally advanced HNC (stage III /IV) to receive radical
radiotherapy alone (n = 213) or with cetuximab (n = 211).
Cetuximab was given as bolus dose of 400 mg/m2 a week
earlier of radiotherapy followed by 250 mg/m2 weekly
concurrent with radiotherapy for 7 weeks.  Combination
therapy significantly prolonged the median duration of loco
regional disease control (24.4 vs. 14.9 months, HR, 0.68; p =
0.005) with control rates of 63%, 50% and 47% at 1, 2 and 3
years respectively, versus 55%, 41% and 34% (p<0.01 at 3
years) (Figure 3A). A 32% risk reduction for loco regional
progression was achieved with combination treatment.
Median OS improved with addition of cetuximab (49 vs. 29.3
months) at median follow-up of 4.5 years (p = 0.03), with 26%
risk reduction for death (HR, 0.74) (Figure 3B).19
In all studies described above, patients who received
cetuxiamab; responses were higher for those who developed
cetuximab associated skin rash.
401 J Pak Med Assoc
Figure 2: Survival Analyses - Progression-free survival (Panel A) and overall
survival (Panel B) (With permission from Ref: No. 13).
Panitumumab:
Panitumumab is fully humanized monoclonal
antibody for EGFR which inhibits the EGFR mediated
cellular actions like dimerization of the receptor, tyrosine
autophosphorylation, tumour growth and induction of
apoptosis.20,21
Panitumumab for Metastatic Colorectal Cancer
(mCRC):
Patients with chemotherapy refractory mCRC were
registered in a phase III trial to receive panitumumab with BSC
(n = 231) or BSC alone (n = 232). Panitumumab was
administered at 6mg/kg over 60 minutes every other week.
From BSC group 176 patients crossed over to treatment arm.
Patients in treatment cohort had prolonged PFS (8 weeks vs. 7.3
weeks, p<0.0001) with 46% decrease in relative progression
rate (HR, 0.54). After a minimum follow-up of 12 months, more
patients in treatment arm achieved PR (10% vs. 0%) and SD
(27% vs. 10%). Median response duration was 17 weeks. No
significant difference for OS was demonstrated. Approximately
90% patients developed skin related toxicities on panitumumab
and grade 3/4 hypomagnesemia in 3% patients.21
Lapatinib:
Lapatinib is an oral tyrosine kinase inhibitor (TKI)
with activity against Her2 and EGFR with the added
advantage of crossing blood brain barrier. It has shown
promising results in breast cancer treatment.22
Lapatinib for Metastatic Breast Cancer (MBC):
In a randomized, phase III trial patients with locally
advanced or MBC with Her2 amplification and prior
treatment with anthracycline, taxanes and trastuzumab were
randomized to receive lapatinib and capecitabine (n = 163) or
capecitabine alone (n = 161). More patients had PD in
monotherapy arm (HR, 0.49; p<0.001). The median TTP (8.4
vs. 4.4 months) and ORR (22% vs. 14%, p = 0.09) were better
for combination therapy. Hand-foot syndrome, diarrhoea,
rash, fatigue, nausea and vomiting were common AEs.23
Several trials are ongoing to assess the role of lapatinib
in the treatment of breast cancer in adjuvant, neo-adjuavant
and metastatic setting.22
Gefitinib:
Targeted therapy against EGFR in NSCLC has shown
promising results as second or third line therapy. Gefitinib is
an oral selective TKI.24
Gefitinib for Non-Small Cell Lung Cancer
(NSCLC):
Iressa Dose Evaluation in Advanced Lung Cancer
(IDEAL 1), a phase II, international trial, randomized
previously treated NSCLC patients to receive gefitinib at a
dose of 250 mg/day (n = 104) and 500 mg/day (n = 106). RR
(18.4% and 19%), PFS (2.7 months and 2.8 months) and OS
(7.6 months and 8 months) were observed for low and high
dose gefitinib respectively. Common AEs were skin rash and
diarrhea.24
In IDEAL 2 trial patients with symptomatic NSCLC
with stage III/IV or PD were given gefitinib at 250 mg/d (n =
106) or 500 mg/d (n = 115). More than 50% patients
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Figure 3A: Kaplan-Meier Estimates of Locoregional Control among All Patients
Randomly Assigned to Radiotherapy plus Cetuximab or Radiotherapy Alone. The
hazard ratio for locoregional progression or death in the radiotherapy plus-
cetuximab group as compared with the radiotherapy-only group was 0.68 (95
percent confidence interval, 0.52 to 0.89; P = 0.005 by the logrank test). The dotted
lines indicate the median durations of  ocoregional control.
Figure 3B: Kaplan-Meier Estimates of Overall Survival among All Patients
Randomly Assigned to Radiotherapy plus Cetuximab or Radiotherapy Alone. The
hazard ratio for death in the radiotherapy-plus-cetuximab group as compared with
the radiotherapy-only group was 0.74 (95 percent confidence interval, 0.57 to 0.97;
P = 0.03 by the log-rank test). The dotted lines indicate the median survival times.
experienced some relief of their symptoms after 1 week of
therapy. Rate of symptom improvement was 43% and 35% for
low and high dose respectively. The radiographic responses
were 12% and 9% with estimated 1 year survival of 27% and
24% for low and high dose gefitinib respectively. Major
toxicities were skin rash and diarrhea. Best responses were
achieved for female sex, adenocarcinoma type and non-
smokers.25
Southwest Oncology Group Study S0126, enrolled
patients with stage IIIB/IV advanced bronchioloalveolar
carcinoma to receive gefitinib at 500 mg/d. Of 145 accrued
patients 101 were chemo-naïve while 45 had received some
treatment. After a median follow-up of 22 months PFS was 4
months for chemo-naïve patients and 3 months for previously
treated patients. OS at 1 year was 51% for all patients and at 2
year OS was 39% for chemo-naïve patients and 27% for
treated patients. Female gender, skin rash, no history of
smoking and PS of 0/1 were associated with better
responses.26
Erlotinib:
Erlotinib is an oral TKI and targets EGFR.
Erlotinib for Non-Small Cell Lung Cancer
(NSCLC):
National Cancer Institute of Canada Clinical Trials
Group study (BR.21) accrued patients with progressive
NSCLC with previous chemotherapy and randomized them to
receive erlotinib (n = 488) or placebo (n = 243). Primary end
point was OS. ORR was 8.9% for erlotinib vs. <1% for
placebo arm (p<0.001). Patients treated with erlotinib lived
longer (median 6.7 vs. 4.7 months, p<0.001). Female gender,
Asian race, history of no smoking, adenocarcinoma and
EGFR expression were associated with better responses. Skin
rash and diarrhoea were most common AEs requiring dose
modification.27
TRIBUTE (Tarceva responses in conjunction with
paclitaxel and carboplatin), a phase III trial however
demonstrated no benefit of erlotinib except for in a subset of
patients who were never smokers.28
Erlotinib for Pancreatic Cancer:
Patients with advanced or metastatic pancreatic
cancers were assigned to receive gemcitabine with erlotinib (n
= 285) or with placebo (n = 284). OS was longer for erlotinib
arm (HR, 0.82) with 1 year survival of 23% versus 17%.
Median PFS was 3.75 months vs. 3.55 months (HR, 0.77) for
erlotinib arm. Skin rash was associated with better disease
control.29
Imatinib:
Imatinib mesylate an oral TKI with the activity against
BCR-ABL protein, c-KIT and platelet derived growth factor
receptor (PDGFR). Imatinib has established its efficacy in
chronic myeloid leukaemia and being also used in certain
solid malignancies which express c-KIT.30
Imatinib in Advanced Gastrointestinal Stromal
Tumour (GIST):
GISTs are mesenchymal malignancies and arise from
Cajal cells of intestinal wall. GISTs express KIT and PDGFR
and are resistant to conventional chemotherapeutic agents.
Role of radiation is not established yet. Survival is poor for
metastatic GIST.
In a pilot study, 23 patients with high risk GIST were
treated with imatinib in adjuvant setting after R0 resection.
Comparison was made with 48 historical cases. After 40
months of follow-up, only 1 of 23 patients had recurrence as
compare to 32 of 48 patients without treatment.31
In a randomized study patients with advanced or
metastatic GIST were assigned to receive imatinib at 400
mg/d (n = 473) or 400 mg twice a day (n = 473). In ITT
analysis responses were almost equal for both doses with CR
of 5% and PR for 45% - 48%. Estimated OS for 2 years was
69% and 74% for once and twice daily dose respectively.
Dose modification, treatment discontinuation and AEs were
more common for twice daily dose arm.30
Sunitinib:
Sunitinb is an oral TKI with activity against VEGF and
PDGFR.
Sunitinib for Renal Cell Carcinoma (RCC):
In a phase III trial patients with metastatic RCC were
randomized to receive sunitinib (n = 375) or IFN (n = 375).
ORR for sunitinib arm was 31% versus 6% (p<0.001), all
were PR. Median PFS was 11 months for sunitinib and 5
months for IFN (Figure 4). Although median OS has not been
reached in either arm but seems to be better in sunitinib arm.
Grade 3 AEs in sunitinib arm were diarrhoea, vomiting and
hand-foot syndrome.32
Sunitinib for Gastrointestinal Stromal
Tumour (GIST):
Patients with metastatic and imatinib resistant GIST
were randomized to receive sunitinb (n = 207) or placebo (n
= 102). In ITT analysis TTP was substantially lengthier for
sunitinib (27.3 vs. 6.4 weeks, p<0·0001). PR was obtained
for 7% patients while 58% had SD and 19% experienced
PD. Major AEs were diarrhoea, fatigue, hand-foot
syndrome and skin changes.33
403 J Pak Med Assoc
Sorafenib:
Sorafenib is also an oral TKI with activity against
multiple TKs.
Sorafenib for Renal Cell Carcinoma:
Treatment Approaches in Renal Cancer Global
Evaluation Trial (TARGET), a phase III study enrolled
patients with RCC to receive sorafenib (n = 451) or placebo
(n = 452).  Median PFS was 5.5 months for sarfenib and 2.8
months for placebo arm (p<0.001). Of patients in sorafenib
arm 1 patient achieved CR while the PR and SD was seen
in 10% and 74% respectively. No patient in placebo arm
observed CR while PR and SD was achieved by 2% and
53% respectively. Major AEs including deaths were more
common in sorafenib group including cardiac ischaemia,
diarrhoea, hand-foot syndrome and fatigue.34
Sorafenib for advanced Hepatocellular
Carcinoma (HCC):
HCC is a common malignancy in Asia and Africa
and most of the time is advanced and incurable. So far
treatment options have not improved the OS remarkably
and responses are poor with chemotherapy.
In Sorafenib Hepatocellular Carcinoma Assessment
Randomized Protocol (SHARP), a multicentre, placebo-
control, randomized phase III trial accrued patients
histologicaly proven and treatment naive HCC with Child-
Pugh liver function class A. Patients were randomized to
sorafenib (n = 299) and placebo (n = 303) arms. OS was
improved by 44% for sorafenib arm (10.7 vs. 7.9 months, p
= 0.0006). Disease control rates were also better for
sorafenib as well (43% vs. 32%). None of patient from both
groups achieved CR. AEs were diarrhoea, hand-foot
syndrome and bleeding, liver dysfunction, weight loss and
hypophosphataemia.35
Conclusion 
Modern management of cancer therapy has been
revolutionalised by the introduction of targeted agents,
although not all of the agents have proven to be equally
efficacious, there is a real interest generated in the oncology
community to further develop on this form of relatively less
toxic way to treat cancers. 
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